Aptose Biosciences Aktie - APS

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

2,90

Gebot

2,88

Fragen

3,08

Volumen

4.584

2,98 Tagesbereich 3,10

0,155 52-Wochen-Bereich 5,80

Handelsende

2,80

Handelsbeginn

3,10

Letzte Trade

100

2.9

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

33.496

Finanzvolumen

VWAP

Aptose Announces Auditor Not Standing for Re-Appointment

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose Reports Year End 2024 Results and Corporate Highlights

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS...

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

TUS+VEN+AZA triplet achieves complete responses (CRs) in difficult-to-treat TP53-mutated/CK AML and...

Aptose Announces Reverse Share Split

SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AMLTUS+VEN+AZA triplet achieves...

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.89	-23.4828496042	3.79	3.79	2.55	7123	2.96518217	CS
4	-1.99	-40.6952965235	4.89	5.8	1.98	8989	3.26581322	CS
12	2.65	1060	0.25	5.8	0.155	33496	0.62184761	CS
26	2.35	427.272727273	0.55	5.8	0.155	35147	0.46050377	CS
52	1.24	74.6987951807	1.66	5.8	0.155	21311	0.54519641	CS
156	-19	-86.7579908676	21.9	23.55	0.155	15491	6.68528504	CS
260	-171.1	-98.3333333333	174	189.3	0.155	29829	57.36556618	CS

APS - Frequently Asked Questions (FAQ)

What is the current Aptose Biosciences share price?

The current share price of Aptose Biosciences is $ 2,90

What is the 1 year trading range for Aptose Biosciences share price?

Aptose Biosciences has traded in the range of $ 0,155 to $ 5,80 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
BABYElse Nutrition Holdings Inc	$ 0,015 (50,00%)	39,5k
EXROExro Technologies Inc	$ 0,17 (21,43%)	1,2M
AABAberdeen International Inc	$ 0,03 (20,00%)	1.000
APLIAppili Therapeutics Inc	$ 0,03 (20,00%)	18k
PPRPrairie Provident Resources Inc	$ 0,035 (16,67%)	2,65k
XMF.AM Split Corp	$ 0,45 (-43,04%)	2,5k
BCTBriaCell Therapeutics Corp	$ 7,26 (-14,08%)	66,99k
NGNovaGold Resources Inc	$ 6,16 (-10,60%)	800,16k
GENMGeneration Mining Limited	$ 0,175 (-7,89%)	125k
AVCNAvicanna Inc	$ 0,245 (-7,55%)	165,03k
RYRoyal Bank of Canada	$ 163,28 (0,15%)	14,78M
MFCManulife Financial Corporation	$ 41,93 (0,19%)	10,79M
CNQCanadian Natural Resources Ltd	$ 40,69 (0,00%)	8,93M
TRPTC Energy Corporation	$ 68,81 (0,34%)	8,77M
ENBEnbridge Inc	$ 64,02 (-0,36%)	7,99M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Aptose Biosciences Inc (APS) Börsenkurse

Aptose Biosciences Inc (APS)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

APS Neueste Nachrichten

Aptose Announces Auditor Not Standing for Re-Appointment

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Aptose Reports Year End 2024 Results and Corporate Highlights

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Aptose Announces Reverse Share Split

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Announces Auditor Not Standing for Re-Appointment

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Aptose Reports Year End 2024 Results and Corporate Highlights

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Aptose Announces Reverse Share Split

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Announces Positive Decision by Nasdaq Hearings Panel

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

APS - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen